Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence
Open Access
- 12 April 2021
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 10 (1) , 349-360
Abstract
Introduction Persistence to multiple sclerosis (MS) disease-modifying therapy is fundamental for maximal treatment outcomes. Diroximel fumarate (DRF) is approved in the USA for relapsing MS. Following oral administration, DRF is metabolized to monomethyl fumarate, the active metabolite of dimethyl fumarate (DMF). DRF showed clinically significant improvements in gastrointestinal (GI) tolerability versus DMF in a head-to-head clinical trial; however, real-world persistence/adherence has not been assessed. We evaluated persistence/adherence in DRF-treated patients in a real-world clinical practice. Methods This retrospective analysis of the AcariaHealth Specialty Pharmacy Program included patients initiating DRF from 4 December 2019 through 3 April 2020 and followed until data extraction (31 August 2020). Exclusion criteria included undetermined treatment status (e.g., DRF prescription transfer to a different pharmacy). Endpoints included persistence (overall proportion of patients remaining on DRF), discontinuation rate due to GI adverse events (AEs), and adherence (proportion of days covered [PDC]). GI AEs included GI-related AEs occurring at any time, or any unknown AE without details about the nature of the event if the unknown AE occurred ≤ 90 days after DRF initiation. Results Overall, 160 patients with MS were included. Median (range) patient age was 51 (20−79) years, 80.6% (129/160) of patients were female, and 16.3% (26/160) had prior DMF treatment. Median (range) treatment duration was 7.6 (0.1−10.4) months. Estimated proportion of patients remaining persistent on DRF treatment at 8 months was 88.6% (95% confidence interval [CI] 82.5–2.7). Overall, 3.8% (6/160) of patients discontinued due to GI AEs. Mean PDC was 91.4% (95% CI 89.1−93.7). In a DMF-to-DRF switch subgroup, 92.3% (24/26) remained persistent on DRF, and 3.8% (1/26) discontinued DRF due to GI AEs. Conclusion This real-world analysis of DRF-treated patients showed high overall persistence, low discontinuation rate due to GI AEs, and high adherence to therapy, aligning with expectations based on DRF clinical trials. Data were consistent in the DMF-to-DRF subgroup. InfographicKeywords
Funding Information
- Biogen
This publication has 30 references indexed in Scilit:
- Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherenceRespiratory Medicine, 2016
- Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE)International Journal of MS Care, 2016
- Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl FumarateInternational Journal of MS Care, 2015
- Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literaturePatient Preference and Adherence, 2014
- Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple SclerosisJournal of Managed Care Pharmacy, 2013
- Evaluating Risks, Costs, and Benefits of New and Emerging Therapies to Optimize Outcomes in Multiple SclerosisJournal of Managed Care Pharmacy, 2012
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple SclerosisNew England Journal of Medicine, 2012
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple SclerosisNew England Journal of Medicine, 2012
- Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosisAdvances in Therapy, 2010
- Good and poor adherence: optimal cut-point for adherence measures using administrative claims dataCurrent Medical Research and Opinion, 2009